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Abstract
Background: Traumatic brain injury (TBI) is a major risk factor for the development of multiple neurodegenerative
diseases, including Alzheimer’s disease (AD) and numerous recent reports document the development of dementia after
TBI. Age is a significant factor in both the risk of and the incidence of acquired brain injury. TBI-induced inflammatory
response is associated with activation of brain resident microglia and accumulation of infiltrating monocytes, which plays
a pivotal role in chronic neurodegeneration and loss of neurological function after TBI. Despite the extensive clinical
evidence implicating neuroinflammation with the TBI-related sequelae, the specific role of these different myeloid cells
and the influence of age on TBI-initiated innate immune response remain unknown and poorly studied.
Methods: We used gene profiling and pathway analysis to define the effect of age on inflammatory response at the time
of injury. The recruitment of peripheral CCR2+ macrophages was delineated using the CX3CR1GFP/+CCR2RFP/+ reporter
mouse. These responses were examined in the context of CCR2/5 antagonism using cenicriviroc.
Results: Unsupervised gene clustering and pathway analysis revealed that age predisposes exacerbated inflammatory
response related to the recruitment and activation of peripheral monocytes to the injured brain. Using a unique reporter
animal model able to discriminate resident versus peripherally derived myeloid cells, we demonstrate that in the aged
brain, there is an increased accumulation of peripherally derived CCR2+ macrophages after TBI compared to young
animals. Exaggerated recruitment of this population of cells was associated with an augmented inflammatory response in
the aged TBI animals. Targeting this cellular response with cenicriviroc, a dual CCR2/5 antagonist, significantly ameliorated
injury-induced sequelae in the aged TBI animals.
Conclusions: Importantly, these findings demonstrate that peripheral monocytes play a non-redundant and contributing
role to the etiology of trauma-induced inflammatory sequelae in the aged brain.
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Background
Traumatic brain injury (TBI) is an environmental risk
factor for the development of many neurological disor-
ders including degenerative diseases such as Alzheimer’s
and early onset dementia [1, 2]. Age significantly
increases both the risk and incidence of acquired brain
injury [3]. Elderly individuals are particularly vulnerable
to TBI and have clinically worse outcomes after TBI
with increased morbidity and mortality, and reduced
functional recovery [4, 5]. While age as a prognostic
factor after TBI has long been recognized [6], limited
attention has been devoted to understanding and modu-
lating the pathologic processes that contribute to poor
outcomes seen in aged individuals.
Brain injury initiates an immediate response involving
multiple cellular effectors of the innate immune re-
sponse, notably the brain’s resident tissue macrophage
and microglia, as well as the recruitment of peripherally
derived monocytes/macrophages presumably through
the disruption of the blood-brain barrier [7–9]. Aging in
humans and rodents has been shown to alter this
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response [10, 11]. In the current study, we used un-
supervised gene clustering and pathway analysis to de-
fine the effect of age on injury-induced inflammatory
sequelae. Our data show that age predisposes the injured
brain to an exaggerated inflammatory response involving
the enrichment of chemotactic mediators associated
with the recruitment and activation of the peripheral
monocytes. Specifically, our data show that aged TBI an-
imals have an exacerbated response in the production of
ligands that bind to both CCR2 and CCR5 at a critical
time point associated with migration of peripheral
monocytes/macrophages to the injured brain paren-
chyma. This molecular response was paralleled by an
increased recruitment of CCR2+ macrophages to the in-
jured brain of aged mice. Given the exacerbated CCR2/5
cellular and molecular signatures, we used a novel small
molecule antagonist for CCR2/5 to abrogate this pheno-
type. Using a clinically relevant pharmacological ap-
proach, our data show that the age-related phenotype in
response to injury is significantly mitigated in treated
animals. These data implicate a new important role for
the accumulation of monocyte/macrophages in the
maintenance of neuroinflammatory sequelae following
neurotrauma in the aged brain.
Methods
Animals
All experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of the University of
California (San Francisco, CA). Adult 3- (young) and 23-
month-old (aged) male and female CX3CR1GFP/+CCR2RFP/+
(double heterozygous (Dbl-Het)) and C57BL6/J (wild type
(WT)) male mice were used for all experiments. Dbl-Het
mice (n = 16) were generated as previously described [12]
and genotyped using a commercial service (Transnetyx),
while WT mice (n = 48) were purchased from the National
Institute on Aging animal colony. Mice were group housed
in environmentally controlled conditions with reverse light
cycle (12:12 h light:dark cycle at 21 ± 1 °C) and provided
food and water ad libitum.
Surgical procedure
All animals were randomly assigned and divided as
equally possible between sexes (Dbl-Het) to their treat-
ment group. Animals were anesthetized and maintained
with 2.5 % isoflurane with a non-rebreathing nose cone
and passive exhaust system connected to a stereotaxic
frame (David Kopf). Once animals were secured with
non-traumatic ear bars, eye ointment was applied and
their heads were cleared of any hair around the scalp.
Following betadine application, a midline incision was
made through the scalp. TBI was reproduced using the
controlled cortical impact model in the parietal lobe as
previously described [13]. A craniectomy was created
using an electric microdrill with center point to the co-
ordinates: 2.0 mm; mediolateral, 2.0 mm, with respect to
the bregma. Explicit attention was paid to prevent dam-
age to the dura during craniectomy; any animal in which
the dura was disrupted, as assessed by excessive bleed-
ing, was omitted from the study and replaced by another
littermate. After craniectomy, contusion was achieved
using a 3.0-mm convex tip attached to an electromag-
netic impactor (Leica) mounted to the digitally cali-
brated manipulator arm. To impact flush with the
natural curvature of the head/tissue, the manipulator
arm was rotated 20° on the vertical axis. The parameters
for impact were for a contusion depth of 0.95 mm (from
dura), velocity was constant at 4.0 m/s, and the impact
was sustained for of 300 ms. After CCI injury, the scalp
was sutured and each animal received 0.5 ml of physio-
logic saline (i.p.) before being placed in a water-heated
incubation chamber (37 °C) until they fully recovered as
exhibited by resumption of movement and grooming.
Sham animals were treated to the above parameters, ex-
cept that the CCI injury was omitted. All animals fully
recovered from surgical procedures and exhibited nor-
mal weight gain for the duration.
Tissue collection
All mice were euthanized using a mixture of ketamine
(150 mg/kg)/xylazine (15 mg/kg) in accordance with
standard animal protocols. For flow cytometry end-
points; once the animal was completely anesthetized, the
chest cavity was opened and transcardially perfused
using ice-cold Hank’s balanced salt solution without cal-
cium and magnesium (HBSS; Gibco). Immediately after
perfusion, mice were decapitated and the ipsilateral
brain hemisphere was placed into ice-cold RPMI-1640
medium without phenol (RPMI; Gibco). For qRT-PCR
endpoints, animals were rapidly killed via cervical dis-
location. Each brain was quickly removed, and the ipsi-
lateral hippocampi were dissected and snap frozen.
Cenicriviroc administration
Cenicriviroc (CVC; Tobira Therapeutics), a small mol-
ecule dual antagonist for the human orthologs of CCR2
and CCR5 was dissolved in solution of 0.5 % hydroxypro-
pyl methylcellulose (vehicle; HPMC + 1.0 % Tween80) to
5 mg/mL. Aged TBI animals were randomly divided be-
tween two treatment groups; vehicle and CVC. Two hours
following surgery, animals were dosed at 100 mg/kg BID
via oral gavage at 2 and 10 h post-surgery intervals. This
treatment strategy was chosen to provide sufficient cover-
age of CCR2/5 through 24 h, with peak plasma concentra-
tions of CVC reached by hour 2 (data not shown).
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Flow cytometry
Brain hemispheres in RMPI were used for leukocyte isola-
tion following standard procedures [14]. Fc receptor
blocking was performed before all staining procedures
using an anti-CD16/32 antibody (BD Pharmigen). The fol-
lowing reagents were used for labeling isolated macro-
phages: ZombieAqua (BD Biolegend), CD11b Alexafluor
700 (BD Pharmigen), and F4/80 APC (Invitrogen) CD45
FITC (AbD Serotec) Ly6C PE (AbD Serotec). Mandibular
blood draws from naïve CCR2RFP/RFP and CX3CR1GFP/GFP
mice were used as positive controls for RFP and GFP
expression, respectively. Additionally, naïve WT isolated
leukocytes served as negative control for RFP and GFP
expression. Spectral compensation was achieved using
polystyrene microparticles (BD Pharmigen) in combin-
ation with each of the above listed conjugated antibodies
following manufacturer’s suggested protocol. Standard
staining procedures were conducted as previously de-
scribed [14] before analysis on FACSAria III cell sorter
(BD Biosciences). Gating parameters for both WT and
Dbl-Het endpoints were used as previously described [13].
All samples were run in duplicate. Flow cytometric data
were analyzed using FlowJo (Treestar; v9.9).
qRT-PCR
Dissected ipsilateral hippocampi were used for all gene
expression analyses. RNA isolation and cDNA conver-
sion were completed as previously described [13]. RNA
concentration and quality were determined using a
NanoDrop (Thermo Scientific). Three hundred nano-
grams of RNA was reverse transcribed using High-
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). For inflammatory profiling arrays [15],
(Qiagen, #330131) equal volumes of cDNA for each
sample were pooled (n = 8 animals/group/pool) and run
on a single plate per condition (e.g., young sham, young
TBI, aged sham, and aged TBI); cycling conditions were
followed as suggested by manufacturer. Select analytes
from the profiling arrays were validated using individual
samples (n = 8/group) carried out in duplicate using
SYBR Green Master Mix (Applied Biosystems) following
manufacturer’s suggested protocol. The relative expres-
sion of target genes was determined by the 2−ΔΔCt
method and normalized against beta-actin gene expres-
sion using a Statagene Mx3005P Real-Time PCR system.
Specifically, the multiple genes were analyzed using the
































CGGAAC). All primer pairs were independently validated
using a standard curve of serially diluted mouse cDNA be-
fore use in any endpoint. In each PCR analysis, template
and RT controls were included to account for contamin-
ation. Gene expression data are represented as the Log2
fold change relative to young sham or to aged TBI-vehicle
(for CVC endpoints).
Hierarchical clustering analysis
Multi Experiment Viewer (v4.8) was used for hierarch-
ical cluster analysis. This was performed using Pearson’s
correlation for distance measure algorithm with average
linking clustering parameters to identify multiple sam-
ples with similar expression patterns.
Ingenuity Pathway Analysis (IPA)
Data from mini arrays were analyzed using IPA. Differ-
entially expressed genes (young TBI, aged sham, and
aged TBI versus young sham) were uploaded into IPA
and refined to limit only expression values of ±1.5-fold
change before core analyses were commenced. Core ana-
lyses of the three groups were analyzed by comparison
for the diseases and biological function analyses. These
functional analyses were sorted by activation z-score of
aged TBI group in a descending list, with exogenous
chemicals omitted.
Statistical analyses
All analyses were performed in Prism v6.0 (GraphPad)
using Student’s t test and one-way ANOVA with Tukey
Morganti et al. Journal of Neuroinflammation  (2016) 13:80 Page 3 of 12
HSD correction for multiple comparisons for both flow
cytometry and gene expression analyses. Significance for
all measures was assessed at p < .05.
Results
Age alters gene expression profiles as a response to
injury
We first conducted gene profiling of the injured paren-
chyma to examine the effect of age upon neuroinflam-
matory response to injury. Unsupervised hierarchical
clustering (Fig. 1) revealed unique arrangements of both
enriched and downregulated responses as a result of in-
jury and/or age. Of these expression clusters, we exam-
ined three that visually represented alignment of genes
that were downregulated in the aged TBI group (Fig. 1;
green), upregulated in the aged TBI group (Fig. 1; red),
and upregulated as a result of injury (Fig. 1; aquamar-
ine). In general, the downregulated genes of the green
cluster represented a repressed inflammatory function as
a combination of age and injury. By contrast, the red
cluster linked a group of genes related to recruitment
and activation of pro-inflammatory monocytes. Notably,
within this expression cluster, our data show increased
responses of several CCR2 and CCR5 cognate ligands
(e.g., CCL2, CCL7, CCL8, CCL5). While the aquamarine
(Fig. 1) cluster was distinct from the changes found
within the red cluster, there was a similar activation pro-
file found between both TBI groups hierarchically. There
was a heterogeneous mix of chemokines, cytokines, and
signal transducers, and metabolic mediators found
throughout this gene cluster, which seem to be indicative
of a general inflammatory response to brain injury, as
there was little to no activation of these mediators in the
aged sham group (Fig. 1).
Selected genes were validated within each of the green,
red, and aquamarine clusters of interest. In line with the
pooled observations from the array and cluster, four
genes from the green cluster (Fig. 1): CD163, CX3CL1,
JAK2, and JMJD3 were disproportionately downregu-
lated in the aged TBI group, compared to young TBI
(Fig. 2a). Potentially indicating that as a result of age,
there is a maladaptive response to injury related to the
Fig. 1 Inflammatory profiling of the TBI brain. Ipsilateral hippocampi
pooled from sham and injured animals (n = 8/group) of 3-month
(young; Y) and 23-month (aged; A) 24 h after surgery for gene array
analysis. Inflammatory profiling array revealed clusters of enrichment
and downregulation of genes across three groups; young TBI, aged
sham, and aged TBI, relative to young sham expression levels, all
data were Log2 transformed. Three specific clusters were examined,
wherein the genes within the green cluster were downregulated in
the aged TBI group, the red gene cluster showed marked enrichment
for aged TBI, and lastly the aquamarine cluster showed similar
enrichment of genes as a response to TBI, regardless of age. In
heatmap; teal downregulated, red upregulated
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restraint of macrophage activation, similar to what is ob-
served in humans [16]. Interestingly, we show that the
anti-inflammatory [17] chemokine CX3CL1 is signifi-
cantly downregulated in the aged TBI group compared
to young animals following TBI. These findings are simi-
lar to a report on brain aging in healthy rodents that
showed CX3CL1 expression is decreased with age [18],
which can lead to pro-inflammatory neurotoxic re-
sponses [19, 20].
Comparatively, when we quantified selected genes
from the red cluster (Fig. 1), we found that compared to
young TBI, the aged TBI group had increased expression
of CD86, a marker linked specifically with microglia
[21], as well as CCL8, CCL7, and CCL5, which are li-
gands for CCR2 and/or CCR5 (Fig. 2b). However, we did
not observe an increase of CCL2 gene expression in the
aged TBI group, relative to young TBI as has been previ-
ously reported [22]. Although CCL2 is the strongest
chemoattractant for CCR2+ monocytes/macrophages,
the increased presence of other constituent ligands (e.g.,
CCL8, CCL7, CCL5) may indicate an additive effect. As
a result of age, the increased presence of multiple mono-
cyte chemotactic mediators would allow a greater per-
missive environment for increased recruitment.
Similarly, validation of selected genes within the aqua-
marine cluster (Fig. 1) showed that there was an exacer-
bated response to injury due to age (Fig. 2c). Specifically,
as a response to injury, aged TBI animals had significantly
increased expression of the inflammatory chemokines
CXCL12, and CCL12, and similarly with pro-inflammatory
cytokines TNFα and IL-1β, as well as PTX3. Arg1 was also
significantly induced relative to young TBI. The elevated
responses we observed are analogous to gene signatures
from isolated CNS monocytes/macrophages in a mouse
model of EAE-induced neuroinflammation [23].
Age alters injury-induced putative upstream and
downstream regulatory networks
Next, we examined the gene expression profiles for
translational observations through identification of puta-
tive upstream and downstream functional analyses using
IPA software. This software converts gene expression
data into recognized functional matrices related to dis-
ease etiology. Using this approach, IPA software identi-
fied regulatory genes associated with predicted upstream
networks (Fig. 3a). Of these putative regulators, we
sorted these responses by descending activation z-score
and selected the top ten regulators that were either up-
or downregulated for each of the three conditions (e.g.,
young TBI, aged sham, aged TBI), relative to young
sham animals. These analyses revealed heterogeneous
regulatory responses with respect to the variety of genes
identified; however, there were a few instances where
these regulators were conserved between conditions.
Fig. 2 Age exacerbates inflammatory gene signatures after TBI. Overall,
the aged TBI group had exacerbated responses, whether up- or
downregulated, to TBI when compared to their young TBI counterparts.
Select genes from each of the three clusters were validated using n= 8/
group. a Genes from the “green” hierarchical cluster aligned with pooled
responses observed in the array. Specifically, detailing that age
significantly affected, via downregulation, gene expression of CD163,
CX3CL1, and JAK2, but not JMJD3, which had only a visual trend.
b Genes selected from the “red” cluster for analysis showed marked
upregulation of CD86, CCL5, CCL8, and CCL7 in the aged TBI group.
c Similarly, genes from the “aquamarine” hierarchical cluster all displayed
significant upregulation in expression response as a function of age,
compared to young TBI. YT young TBI; magenta, AS aged sham;
aquamarine, AT aged TBI; orange. Young sham expression values are
equivalent to zero. Data were analyzed using two-way ANOVA with
Tukey’s PSD for multiple comparisons and presented as mean + SEM.
*p< 0.05, **p< 0.01 comparing young TBI to young sham. #p< 0.05,
##p< 0.01 comparing aged TBI to young TBI
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Fig. 3 (See legend on next page.)
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Interestingly, among the conserved regulators between
both young and aged TBI groups were the activation of
CCL2 (Fig. 3b) and downregulation of GPX1 (Fig. 3c),
involved in the recruitment of CCR2+ leukocytes and
regulation of oxidative stress, respectively.
Comparatively, we examined if these gene expression
responses were predictive of downstream disease-based
functions using IPA software. Using IPA comparative
analysis, we next sorted the top ten biological functions
by the activation z-score in the aged TBI group. Of the
top ten functions generated, there was a general theme
of each related to innate immune response. In particu-
lar, there was an overrepresentation with both the dif-
ferentiation and activation of monocytes in the aged
TBI group, relative to young TBI (Fig. 4a; arrow).
Examination of the putative response network associ-
ated with the activation of monocytes (Fig. 4a) revealed
significant differential expression patterns in the media-
tors affecting this response system (Fig. 4b). Principal
to this response was the induction of pro-inflammatory
and chemotactic mediators within the CC and CXC
motifs.
Age exaggerates the accumulation of CCR2+ monocytes
following trauma
We next sought to determine if the predictive responses
generated in IPA translated to in vivo reactions. Using
the Dbl-Het reporter mice, our data show that aging re-
sults in a small, but significant increase in the mean
number of CCR2+ infiltrated monocytes/macrophages
relative to young mice (Fig. 4c). When compared to this
result, following brain injury, there is a much greater re-
cruitment and infiltration of CD11b+F4/80+CCR2+ mac-
rophages into the parenchyma as compared to young
animals. The nature of these cells in the diseased brain
remains controversial, as there are reports detailing both
beneficial and detrimental actions of this population of
monocytes varying among disease models [13, 24–26].
Interestingly, as a response of age, there was a visual in-
crease in the number of resident F4/80+ microglia/macro-
phages (CX3CR1+CCR2−; Fig. 4c), which was exaggerated
in response to TBI. Recent work has shown that this
subpopulation may have distinct roles in the inflammatory
response to trauma [27].
Simultaneous CCR2/5 antagonism abrogates age-related
response to injury
In order to abrogate this response, we treated aged TBI
mice with cenicriviroc (CVC), a potent, oral, dual-
antagonist of CCR2/5, which is currently being evaluated
in a phase 2 clinical trial in adults with non-alcoholic
fatty liver disease and liver fibrosis (NCT02217475). Sep-
arate cohorts of aged TBI animals were treated with ei-
ther vehicle or CVC twice daily several hours after
injury (Fig. 5a). Using this experimental approach, we
observed a significant reduction in the numbers of
CD11b+F4/80+CD45hiLy6C+ macrophages (Fig. 5b,c),
which are analogous to CCR2+ macrophages, recruited
into the diseased brain [12, 28].
CVC treatment mitigates the age-related inflammatory
response to TBI
We next examined whether this treatment had any effect
within the previously defined (Fig. 1) expression patterns
identified by hierarchical clustering. Treatment with
CVC significantly increased the expression of the genes
in the green “restraint and anti-inflammatory” cluster
(Fig. 6a), while significantly downregulating genes from
the red “inflammatory chemotactic” cluster (Fig. 6b) and
aquamarine “injury-induced inflammation” (Fig. 6c) gene
clusters. The putative upstream network analysis pre-
dicted a proclivity for exaggerated oxidative stress re-
sponse in the aged TBI group through downregulation
of GPX1-regulated pathways (Fig. 3c). Importantly, we
have recently shown that CCR2 antagonism ameliorates
constituents mediating oxidative stress response follow-
ing TBI through reduction of NADPH oxidase (NOX2)
complex [13]. In agreement with those findings, our
current data show that CVC treatment significantly
downregulated multiple constituents of the neurotoxic
ROS complex, NOX2 (Fig. 6d), which were previously
shown to be upregulated in aged animals following TBI
[22].
Discussion
The brain’s response to neurotrauma initiates a wide
range of molecular signaling mechanisms involving a
variety of cell types [29, 30]. Of principle concern is the
activation of the myeloid constituents, microglia, and
monocytes, due to their involvement and propagation of
(See figure on previous page.)
Fig. 3 IPA upstream analysis displays heterogeneous regulatory components associated with inflammatory response. Gene array data were
loaded into IPA software; genes with a fold change (relative to young sham) ≥1.5 or ≤−1.5 were included for upstream regulator analysis.
a Upregulated and downregulated molecules were sorted via their respective activation z-score and the top ten regulators (up and down) are
presented for each condition. b, c Representative regulatory networks for putative upstream mediators associated with young TBI and aged TBI,
with CCL2 representing an upregulated response and GPX1 representing a downregulated response. Both CCL2 and GPX1 show dissimilar
expression responses for young TBI versus aged TBI
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a variety of acute and chronic disorders [31]. The ap-
proaches taken in this study define the brain’s inflamma-
tory milieu in response to TBI and how these molecular
patterns are altered as a function of age. The altered
shift in expression patterns of chemotactic mediators in
aged TBI brain created a permissive environment for the
exaggerated influx of peripheral monocytes/macrophages
to the brain. This, in part, may be due to redundant in-
creases in chemokines associated with CCR2/5 signaling.
While the role of these monocyte populations is diverse
across various neurological diseases, we have shown that
these cells augment a pro-inflammatory and potentially
neurotoxic bias in the aged brain. We also used an avail-
able CCR2/5 inhibitor to reduce the accumulation of
pro-inflammatory myeloid cells in the brain. Cumula-
tively, our findings demonstrate that the CCR2-mediated
recruitment of monocytes into the injured brain is a ra-
tional therapeutic target that may abrogate TBI-induced
neuroinflammatory-mediated sequelae.
We recently described the leukocyte-mediated neu-
roinflammatory sequelae associated with this TBI model
in young animals over a detailed time course spanning
acute through chronic time points [13]. Our previous
findings suggest that resident microglia are responsible
for the initiation of specific inflammatory mediators and
infiltrated CCR2+ macrophages significantly augment
this response. However, in the context of aging, recent
work has shown that the aged brain has an altered in-
flammatory profile relative to basal levels of adult mice
[32], potentially priming these systems for maladaptive
responses to insult or injury [33]. In the context of neu-
rotrauma, our current data suggest that age dysregulates
multiple signaling networks associated with the activa-
tion, chemotaxis, and inflammatory response of innate
immune effectors. We have recently shown that these
responses do not fall within the dichotomous constraints
of “M1/M2” polarization [15]. In agreement with or pre-
vious work, our current data indicate that as a result of
age, there is dysregulation across both pro- and anti-
inflammatory mediators. While we highlighted several
instances of exaggerated pro-inflammatory and chemo-
tactic gene profiles using unsupervised hierarchical clus-
tering, we also observed pro-inflammatory mediators
such as CD40, CXCL11, CCL17, CCL19, and IL16 that
were downregulated in the aged TBI group, relative to
young TBI. Given these opposing inflammatory re-
sponses, it is difficult to conclude that TBI in the aged
predisposes a purely pro-inflammatory bias, as there are
both inductions of anti-inflammatory response with
(See figure on previous page.)
Fig. 4 Gene profiling predicts exaggerated activation and recruitment of monocytes in aged TBI. Gene array data were uploaded into IPA software,
genes with a fold change (relative to young sham) ≥1.5 or ≤−1.5 were included for disease and biological function analysis. a Upregulated functions
across all three groups were sorted by activation z-score of the aged TBI group, only the top ten functions are presented with the black arrow
emphasizing the activation of monocytes. b Functional network diagram of predicted and measured regulators is presented for both young TBI and
aged TBI, which highlight an overrepresented activation for this function for aged TBI group. c Using Dbl-Het reporter mice (n = 6/group),
macrophages (CD11b+F4/80+) were delineated based upon their relative expression of GFP (CX3CR1) from RFP (CCR2) by flow cytometry.
There were relatively very few CCR2+ macrophages (blue box) in the sham animals; however, there was a significant increase in this subpopulation due
to age. However, 24 h following TBI, there was a significant increase in the mean number of CCR2+ macrophages (blue box) in the aged animals
compared to young. Data were analyzed using Student’s t test and are represented by the mean + SEM. **p< 0.01
Fig. 5 Dual targeting of CCR2/5 with CVC mitigates TBI-induced
macrophage recruitment. a In WT mice, CVC or vehicle was
administered BID via oral gavage at 100 mg/kg at 2 and 10 h post
surgery before animals were euthanized for various endpoints at
24 h following surgery. b A cohort of WT aged TBI animals (n = 8/
group) was used for flow cytometry analysis of macrophage
infiltration into the injured brain. Twenty-four hours after injury,
there was a significant decrease in the number of peripheral
macrophages (CD11b+F4/80+CD45hiLy6C+) in the CVC-treated
animals compared to their vehicle-treated counterparts
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concomitant downregulation of pro-inflammatory re-
sponses, relative to young injured animals. However, our
current data attribute, in part, that cumulatively, these
maladaptive responses create an overly permissive envir-
onment for the exaggerated recruitment and accumula-
tion of CCR2+ macrophages.
Although CCR2 is expressed on a variety of immune
cells, circulating “inflammatory” monocytes are the main
population that expresses this cytokine receptor [12].
CCR2 is currently known to have five cognate ligands;
CCL2, CCL8, CCL7, CCL13 (human only), and CCL12
[34, 35]. However, there is a degree of promiscuity of the
CCR2 receptor and its ligands as they are known to bind
other C-C receptors; notably CCR5 [36, 37]. Expression
of CCR5, like CCR2, is found on a variety of circulating
immune effectors, but most relevant to our study, is co-
expressed on CCR2+ monocytes [38]. Overall, in the
context of our current findings, the cross-talk and co-
expression of CCR2/5 on monocytes, and enhanced
expression of their cognate ligands may potentiate the
increased recruitment we observed in aged TBI animals.
Therefore, our current data are consistent with the for-
mation of a pro-chemotactic milieu created, in part, by
increased signaling through CCR2/5 expressing cells.
NOX2 activation possesses a neurotoxic nature from
the production of ROS intermediates [39, 40] as well as
maintaining redox pro-inflammatory signaling cascades of
macrophages [41]. Recent work has detailed an increase in
some subunits of the ROS-producing NOX2 complex of
aged TBI animals [22]. Our treatment paradigm with
CVC significantly downregulated the expression of the
multiple subunits that comprise the NOX2 complex, sug-
gesting a decreased propensity for ROS intermediate for-
mation relative to the vehicle-treated animals. These data
align with our previous work implicating CCR2+ macro-
phages as the predominant source for NOX2 gene expres-
sion following TBI [13]. Importantly, in rodent models of
TBI, inhibiting this complex decreased neuronal damage
and improved recovery [42, 43].
Conclusions
Our current study demonstrates that the aged brain’s
response to neurotrauma involves the exacerbated
expression of multiple mediators involved in the re-
cruitment of peripheral macrophages to the injured
parenchyma. Blocking of these innate immune media-
tors via CCR2/5 antagonism significantly blunted their
ingress, while concomitantly reducing inflammatory
and potentially neurotoxic signatures. Intentionally,
we limited the scope of this study to examine the
period following injury where the maximum inflection
of recruited CCR2+ macrophages was previously
known [13], in an effort to define this time point
within the context of age at the time of TBI. Therefore,
the conclusions garnered in this study should not be ex-
panded beyond the presented injury paradigm. Future
work is needed to define how neurotrauma in the context
of age affects inflammatory response in subacute and
chronic periods and whether the responses and treatment
currently examined may produce tangible outcome mea-
sures in those periods.
Fig. 6 Treatment with CVC attenuates age-related inflammatory and oxidative stress responses. a-c In a separate cohort (n = 8/group), inflammatory
clusters were examined for their response to CVC treatment. a–c Correspond to the previously examined green, red, and aquamarine expression
clusters, respectively. d Subunits of the NOX2 complex were measured as a response to CVC treatment (n = 8/group). Gene expression data are relative
to vehicle-treated aged TBI. Vehicle expression values are equivalent to zero. Data were analyzed using Student’s t test are represented by mean +
SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
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